Several antimicrobials act by inhibiting the synthesis of nucleic acids (rifamycins, sulfamides, diaminopyridines), modifying their conformation (quinolones, coumarins) or causing irreversible lesions (nitroimidazoles, nitrofurans). The resistance mechanisms are: a reduction in intracytoplasmic accumulation, modification of the target or the production of a new low-affinity target and, more rarely, enzyme inactivation. Although the mechanisms affecting the targets are specific to each family and can lead to high-level resistance, the reduced permeability of the membrane and the increased efflux are non-specific and result in low-level cross-resistance between several families. The genetic mediation is usually chromosomal for rifamycins and quinolones, although plasmid-mediated resistant genes have been observed. On the other hand, for sulfamides and trimethoprim, plasmid-borne genes are frequent. Resistance to nitroimidazoles and nitrofurans is still not widely understood.
Introduction
Several families of antimicrobials act by inhibiting the synthesis of nucleic acids (rifamycins, sulfamides, diaminopyridines), modifying their conformation (quinolones, coumarins) or causing irreversible lesions (nitroimidazoles, nitrofurans). Some are antibiotics in the strictest sense of the word because they are produced naturally and others are synthetic antimicrobials.
They can be classified according to the different stages in the synthesis of nucleic acids:
-synthesis of puric and pyrimidic nucleotides for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) inhibited by sulfamides and diaminopyridines -replication of DNA inhibited by quinolones and coumarins, and transcription of DNA into RNA inhibited by rifamycins.
Finally, certain antimicrobials directly destroy nucleic acids, such as nitrofurans and nitroimidazoles. The principal molecules are shown in Figure 1 . The resistance mechanisms and their genetic mediation are summarised in Table I .
Inhibition of the synthesis of nucleic bases
Two main families inhibit the synthesis of purine and pyrimidine nucleotides by inhibiting the synthesis of folic acid: sulfamides and diaminopyridines (Fig. 2) . These are synthetic molecules. pyridazine, etc.) and the sulfones (dapsone) inhibit dihydropteroate synthase (DHPS). This enzyme enables bacteria to synthesise dihydrofolic acid from paraaminobenzoic acid (PABA) and dihydropteridine. Sulfamides are structurally similar to PABA and act by competing with the PABA (14, 18) (Fig. 2) . In eukaryotic cells, the folic acid is captured directly in the external environment and therefore the sulfamides are not active.
Sulfamides are broad-spectrum antimicrobials that act on Gram-positive bacteria (including streptococcus, staphylococcus, corynebacterium, Listeria, Nocardia and mycobacteria) and Gram-negative bacteria (enterobacteria, Neisseria). Sulfamides also act on more complex cells such as fungi (Pneumocystis jirovecii) and parasites (Isospora belli, toxoplasma and Plasmodium).
The mechanisms of resistance to sulfamides are (1):
-reduction in the intra-bacterial concentration of sulfamides: this stems from either a reduction in the permeability of the Gram-negative bacterial cell wall by reducing the quantity of porines (22) , or hyper-expression of the resistance, nodulation and cell division (RND) efflux pumps (23) . These mechanisms are not specific to sulfamides because they also concern the efflux of other molecules with a low molecular weight, including hydrophilics such as beta-lactamines, aminoglycosides and quinolones. Mutations in the genes that regulate the synthesis of OmpF (Mar operon) or expression of the efflux pumps (Acr operon) are traditionally observed in enterobacteria (11, 22, 23 Fig. 2 Diagram of the mechanism of action of sulfamides and diaminopyridines -structural modification of the DHPS: these modifications are secondary to structural mutations of the chromosomal gene. For example, in strains of Mycobacterium leprae resistant to dapsone (5) there are folp1 mutations in positions 53 (Thr53Ala, Thr53Ile) and 55 (Pro55Leu). In Neisseria meningitidis (9) or Streptococcus pneumoniae (27) , insertions of several nucleotides are found in the chromosomal gene forming a sort of mosaic gene, resulting from recombination with genes from other bacteria; -production of DHPS enzymes resistant to sulfamides: these enzymes are coded by genes (sul1, sul2, sul3) acquired from other cells and transferred via transposons or integron genetic structures (14) . The gene sul1 characterises class 1 integrons within transposons often carried by plasmids with resistance to multiple antibiotics (multidrug-resistant [MDR] plasmids) (10); -hyperproduction of DHPS.
Diaminopyridines
Diaminopyridines are derived from antiparasitic molecules. Trimethoprim is used mainly as an antibacterial, while pyrimethamine is used as an antiparasitic.
Diaminopyridines act by inhibiting dihydrofolate reductase (DHFR). This enzyme is used to synthesise tetrahydrofolic acid from dihydrofolic acid. Diaminopyridines therefore act in synergy with sulfamides, but at a later stage, by inhibiting the synthesis of folic acid ( Fig. 2) (1).
Trimethoprim is a broad-spectrum antimicrobial that acts on Gram-positive bacteria (including streptococcus and enterococcus, staphylococcus, corynebacterium, Listeria, Nocardia) and Gram-negative bacteria (enterobacteria). However, some Gram-negative species are intrinsically resistant to trimethoprim, e.g. Neisseria, Acinetobacter, Pseudomonas and Campylobacter/Helicobacter. Trimethoprim and pyrimethamine act on Pneumocystis jirovecii and Isospora belli but pyrimethamine is more active on toxoplasma and Plasmodium.
The mechanisms of resistance to diaminopyridines are:
-reduction in the intra-bacterial concentration in Gramnegative bacteria linked to a reduction in the influx or hyper efflux, as for sulfamides (11, 22, 23) ; -production of the enzyme DHFR resistant to the action of trimethoprim. These enzymes are coded by genes (genes 17 to 18 dhfr as described) acquired from other bacteria and transferred via transposons on MDR plasmids, sometimes in integron genetic structures (10);
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-structural modifications of the DHFR, following missense mutations of the chromosomal gene, for example the mutation Ile100Leu in S. pneumoniae (27) ; -increase in the synthesis of the target (DHFR) (14) .
Note that the presence of thymine or thymidine in the culture medium can result in the observation of false resistance to trimethoprim.
Inhibition of DNA replication

Quinolones and fluoroquinolones
Fluoroquinolones are currently among the most heavily prescribed antimicrobials in the world. These antimicrobials are in such common use because of their pharmacodynamic (spectrum) and pharmacokinetic properties (13) .
Nalidixic acid belongs to the pyridone-ß-carboxylic or 4-quinolone family. This synthetic molecule, derived from anti-malarials, is the first of the quinolones and was first used in 1962. The success and development of this family are associated with the addition of a fluorine in C6 of the pyridine cycle and C7 of the piperazyl cycle, opening the door in the 1980s to a new group of quinolones, including the fluoroquinolones.
Antimicrobial activity
The quinolones can be divided into four groups according to their structure ( Fig. 3 ) (all synthetic chemical molecules) and their antimicrobial activity (3, 4) .
The 'classic' quinolones (nalidixic acid, oxolinic acid, pipemidic acid, a first-generation quinolone with a piperazine at C7, and flumequine, a first-generation quinolone with a fluorine at C6) act only on Gram-negative bacteria, especially enterobacteria (Escherichia coli, Proteus, Klebsiella, etc.), Neisseria, Haemophilus spp., Moraxella spp. and Branhamella spp.
The fluoroquinolones (enrofloxacin, marbofloxacin, ciprofloxacin, norfloxacin) have in common a piperazine radical at C7 and a fluorine at C6 of the B-cycle, which makes them at least 100 times more active than the classic quinolones. They therefore act on other Gram-negative bacilli, such as Pseudomonas aeruginosa and legionella, as well as on Gram-positive bacteria such as staphylococcus. Levofloxacin also forms part of this group because of its structure (levogyre isomer of ofloxacin) and its antimicrobial activity.
The new fluoroquinolones (pradofloxacin, moxifloxacin, gatifloxacin) were developed to broaden the spectrum of 
Mechanism of action
Quinolones penetrate Gram-negative bacteria using porines, especially as they are hydrophilic (norfloxacin and ciprofloxacin), while in hydrophobic molecules (e.g. ofloxacin, levofloxacin, moxifloxacin) penetration can also take place through the lipid bilayer. Gram-positive bacteria are penetrated by passive diffusion through the peptidoglycan.
Quinolones inhibit replication and transcription by inhibiting the functioning of bacterial type II topoisomerases, DNA gyrase (still called topoisomerase II) and topoisomerase IV. DNA gyrase is a tetrameric holoenzyme composed of the sub-units GyrA and GyrB in the form GyrA 2 GyrB 2 (Fig. 4) . Topoisomerase IV has a similar structure with sub-units ParC and ParE (13) .
The quinolones attach to the DNA-topoisomerase complex. This complex becomes irreversible, leading to immobilisation of the enzymes that result in bacteriostasis and to the release of DNA double-strand breaks that activate the SOS system and produce the 'poison' effect that is responsible for the intense bactericidal action of quinolones. The details of the steps at cellular level leading to these effects are still poorly understood. The bactericidal effect varies depending on the molecule and the species of bacteria concerned.
Resistance mechanisms
Resistance mechanisms can be classified according to their function: reducing intra-cytoplasmic accumulation by reducing the permeability of the wall or increasing the efflux, reducing the affinity of targets, inactivating enzymes or protecting targets (Fig. 5) . Most of these mechanisms are chromosome-mediated, but plasmid-mediated genes have been described for a decade or so (4, 30) .
Chromosomal resistance
The main mechanism of resistance is associated with mutations in type II topoisomerase structural genes, usually on the genes gyrA or parC, and more rarely on the genes gyrB or parE. These mutations are selected in the presence of quinolone with a frequency of around 1/10 8 . The mutations are found in a region called the quinolone resistance-determining region (QRDR) (12) . We observe the phenomenon of step-resistance, with an increase in the minimum inhibitory concentration (MIC) with each new mutation acquired. The first mutation generally occurs in the topoisomerase for which the quinolone has the greatest affinity, which may vary according to the bacterial species and the quinolone (6, 7). The primary target of ciprofloxacin is sub-unit A of the DNA gyrase in Gramnegative bacilli, while it is sub-unit ParC of the topoisomerase IV in Gram-positive cocci (6) . These mutations of type II topoisomerases confer a high level of resistance. The most frequently observed mutations in E. coli are on the codons 83 (Ser83Leu) and 87 (Asp87His) of GyrA, corresponding to the codons 80 and 84 of ParC.
There are two mechanisms that reduce quinolone accumulation in bacteria. These mechanisms are as described above for sulfamides and trimethoprim, with the addition of major facilitator superfamily (MFS) efflux pumps in Gram-positive bacteria that also result in resistance to quaternary ammoniums in some cases (22, 23) .
Plasmid resistance
For many years, the only known mediation for resistance to quinolones was chromosomal, until the discovery of the gene qnrA1 carried by a strain of Klebsiella pneumoniae, which was isolated in the United States in 1998 (30) . Many other quinolone resistance (qnr) genes have been described since then: qnrA, qnrB, qnrS, qnrC and qnrD, each with several alleles (descriptions can be found online:
Rev. sci. tech. Off. int. Epiz., 31 (1) www.lahey.org) (15) . The Qnr proteins act by protecting the topoisomerases against the action of quinolones. They belong to the family of pentapeptide repeat proteins (PRP), which are formed by a repeat series in tandem with five amino acids (33) . Similar proteins are the protein McbG, which inhibits the microcin B17 in E. coli (MccB17) (12) and the protein MfpA discovered in mycobacteria (20, 30) . The other mechanism with plasmid-mediation is the gene qepA encoding an efflux pump belonging to the MFS family. Another gene, oqxAB, encoding an efflux pump of the RND family, has been described in a strain of E. coli isolated in a pig (29) . OqxAB confers resistance to olaquindox, a quinoline derivative used in veterinary medicine (29) .
The mechanism for inactivating quinolones (Table I) did not exist prior to the description of the plasmidmediated gene aac(6′)-Ib-cr encoding a bifunctional aminoglycoside 6′-N-acetyltransferase capable of acetylating both aminoglycosides and fluoroquinolones (26) . This gene is a variant of the classic gene aac(6′)-Ib that confers resistance to certain aminoglycosides (amikacin, isepamicin, tobramycin). The new enzyme AAC(6′)-Ib-cr includes two mutations (Trp104Arg and Asp181Tyr) that reduce the aminoglycoside resistance but confer resistance to ciprofloxacin and norfloxacin, thanks to the N-acetylation of the secondary amine group of the piperazinyl cycle.
Acquisition of resistance to quinolones
Clinical resistance to quinolones generally results from a combination of several of the resistance mechanisms described above, with each mechanism acquired independently. For example, in E. coli, a level of resistance higher than critical clinical concentrations (0.5 mg/l for ciprofloxacin, for example) is achieved only by a combination of at least two mechanisms, most frequently a mutation of gyrA S83L and an efflux or impermeability. Only a combination of four or five mechanisms (mutations of gyrA and parC + efflux + qnr + AAC-(6′)-Ib-cr + impermeability) can achieve a high level of resistance in E. coli (ciprofloxacin MIC of 16 mg/l). For Staphylococcus aureus, two or three mechanisms are sufficient and for streptococci a single mutation often results in clinical resistance. Nevertheless, resistance is acquired in successive stages and it is therefore very important to be able to detect low levels of resistance, indicating the acquisition of a first resistance mechanism that could lead to the acquisition of clinical resistance.
Coumarins
Coumarin antibiotics include coumermycin and novobiocin, which are natural products from Streptomyces spp. These antibiotics also inhibit type II topoisomerases, DNA gyrase and topoisomerase IV but they use a different mechanism from that of quinolones. They act by competitive inhibition of the hydrolysis of adenosine-5′-triphosphate (ATP), which involves an N-terminal region of the sub-unit GyrB for DNA gyrase and the subunit ParE for topoisomerase IV (19) . Since the sub-units are dimeric in vivo, we understand that coumermycin A, which is virtually the double of novobiocin, can block the two hydrolysis sites while novobiocin blocks only one.
As these molecules have rather a high molecular weight, penetration of the cell wall of Gram-negative bacteria is difficult, resulting in natural resistance to them. They are particularly active on streptococci and staphylococci (MIC from 0.003 to 0.02 mg/l), except for certain species such as S. saprophyticus.
The resistance mechanisms are associated with mutations in sub-unit B of DNA gyrase (codons 136 and 164) (8) .
Transcription inhibitors: rifamycins
The rifamycins, still referred to as ansamycins, are natural products of Streptomyces spp. Their discovery was very important for the treatment of mycobacterial infections, including tuberculosis, caused by the tubercle bacillus (Mycobacterium tuberculosis complex), and leprosy, caused by M. leprae and M. lepraemurium.
The mechanism of these antibiotics inhibits transcription by binding to the beta sub-unit of the RNA polymerase, protein ␤␤′␣2ω, coming between the RNA and the beta sub-unit (16) . This prevents transcription from starting. These molecules are bactericidal antibiotics. They are among the few antibiotics that act on quiescent bacteria, i.e. not in the growth phase. This is why they are the preferred molecules for treating sub-acute and chronic infections.
Antibacterial activity
Rifampicin was discovered by P. Sensi and M.T. Timbal in 1959. It is produced by Streptomyces mediterranei. It acts mainly on Gram-positive bacteria such as streptococci, staphylococci and mycobacteria (Table II) . Even though it also acts on Gram-negative cocci, the walls of Gramnegative enteric or aerobic Pseudomonas bacilli are often impermeable to them.
Resistance mechanisms
Modification of the target by mutations of the rpoB gene
The mutations are selected in the presence of rifamycin at a frequency of around 1/10 -8 . Several mutations can be combined to give a high level of resistance in streptococci and staphylococci (2) .
One region of the gene rpoB is particularly well known in the M. tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. caprae, M. pinnipedii, M. canetti) because it contains all the mutations associated with acquired resistance to rifampicin. This region extends from codon 511 to codon 533 (E. coli numbering system) (21) . In strains resistant to rifampicin, in one case out of two we find the mutation Ser531Leu or Ser83Trp. These mutations are detectable by polymerase chain reaction (PCR) amplification followed by hybridisation or sequencing, and now using commercialised tests: GeneXpert ® MTB/RIF (Cepheid, USA); GenoType ® MTB-DR plus (Hain Lifescience, Germany); InnoLiPA ® Rif-Tb (Innogenetics, Belgium).
Inactivation of rifamycins
This is caused by an ADP ribosylase encoded by the gene arr-3. This gene is found in its natural state in the bacteria that produce it (chromosome-mediated), and has been transferred to Gram-negative bacteria where it is usually plasmid-mediated within the integron or between insertion sequences.
Other mechanisms
An efflux and aggravation of natural impermeability can also be responsible for resistance in Gram-negative bacteria.
Toxic action on DNA
5-Nitroimidazoles
The 5-nitroimidazoles, including metronidazole, ornidazole and tinidazole, are antibiotics that act mainly against anaerobic bacteria because they require a prior reduction of ferredoxins (anaerobic pyruvate metabolism, NO 2 => NH 2 ) in the presence of DNA.
These antibiotics inhibit the synthesis of nucleic acids by binding to the DNA, especially in regions rich in thymidine and adenine. They are bactericidal but the mechanism is poorly understood.
The antibacterial spectrum is narrow and mainly concerns anaerobic bacteria, with Gram-negative bacteria being more susceptible than Gram-positive bacteria. Certain bacteria with a microaerophilic metabolism such as Helicobacter pylori are also susceptible.
The imidazoles are also effective on many parasites: Trichomonas vaginalis, Lamblia (giardia), and Entamoeba histolytica (amoeba).
Resistance mechanisms are rarely observed in anaerobic bacteria. We observe:
-a reduction in intra-bacterial accumulation by a reduction in the influx or efflux (22, 24) -a reduction in nitro-reductase activity.
The nim genes (nimA to nimF) were found in anaerobic bacteria with acquired resistance (25, 28, 31) . These genes encode reductases that cannot activate imidazoles. The genes are transferable because they are plasmid-mediated or transposon-mediated, but some of them can be found in chromosomes. The expression of nim genes is often subject to a promoter introduced upstream of the gene by an insertion sequence (32) .
Resistance is frequently found in H. pylori (30% to 50%) but it is sometimes due to false resistance in vitro because of the difficulty of testing metronidazole in this slowgrowing bacterium. While several genes encoding reductases were blamed (frxA, rdxA), the main culprit was general modification of the oxide-reduction capacity of the bacteria (17) .
Nitrofurans
The nitrofurans need to be transformed into active compounds by reduction, like the nitroimidazoles. The active compound causes lesions of the DNA that are poorly characterised.
Unlike the 5-nitroimidazoles, the reductases produced by aerobic-anaerobic bacteria such as enterobacteria are active and can transform the nitrofurans. That is why these molecules have a broad spectrum of antibacterial activity: Gram-negative bacteria such as enterobacteria (except Proteae) and Gram-positive bacteria such as staphylococci and streptococci.
The acquired resistance mechanisms are poorly understood:
-resistance by reducing the nitroreductase activity due to mutations in the genes nfsA and nfsB -reduction in the accumulation in Gram-negative bacteria.
According to the current state of knowledge, these genes are chromosome-mediated.
